vimarsana.com

Page 271 - நோய் எதிர்ப்பு சக்தி டோவர்டீ நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Powering ahead on Ord cotton gin

Japan emergency state to expand beyond Tokyo as COVID-19 cases climb - media

By Eimi Yamamitsu and Tetsushi Kajimoto TOKYO (Reuters) - Japanese Prime Minister Yoshihide Suga told a meeting of ruling party executives on Tuesday he would declare a state of emergency for the three western prefectures of Osaka, Kyoto and Hyogo to stem the spread of COVID-19, Kyodo news reported. Responding to pressure from Tokyo and three neighbouring prefectures in eastern Japan, Suga last week declared a one-month state of emergency for that region until Feb. 7. But the number of coronavirus cases has also climbed in the west, prompting Osaka, Kyoto and Hyogo to seek a state of emergency too. The government is finalising plans to do so on Wednesday, and could also consider adding the central prefectures of Aichi - home to Toyota Motor Corp - and Gifu, Kyodo reported, citing government sources. Adding those five prefectures would mean a state of emergency for about half of Japan s population of 126 million people. Japan s top government spokesman, Chief Cabinet Secretary Katsunobu

Herd Immunity Won t Happen in 2021, WHO Warns - Even With Vaccines

Augmented RIC No Help in Transplant for AML

email article A sequential augmented reduced-intensity conditioning (RIC) regimen failed to improve post-transplant outcomes for patients with high-risk acute myeloid leukemia (AML) or myelodysplasia (MDS), a randomized trial showed. Neither 2-year overall survival (OS) nor cumulative incidence of relapse improved as compared with standard RIC prior to allogeneic hematopoietic cell transplant (HCT). Detectable measurable residual disease (MRD) prior to transplant was associated with a twofold increase in relapse, but the data showed no evidence of interaction between MRD status and conditioning regimen, reported Charles Craddock, MD, of Queen Elizabeth Hospital in Birmingham, England, and co-authors in the In unrandomized phase II trials and retrospective registry data, the [intensified] protocol, which incorporates additional cytoreductive chemotherapy prior to a fludarabine-based RIC regimen, has been reported to reduce relapse and improve outcomes in high-risk AML or MD

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.